Wells Fargo & Company MN Buys 23,688 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Wells Fargo & Company MN grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 76.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,726 shares of the company’s stock after acquiring an additional 23,688 shares during the quarter. Wells Fargo & Company MN’s holdings in Cellebrite DI were worth $1,206,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $100,000. Polen Capital Management LLC purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $222,000. Victory Capital Management Inc. purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $234,000. HighTower Advisors LLC purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $274,000. Finally, Pictet Asset Management Holding SA purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $283,000. 45.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CLBT. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a report on Wednesday, April 2nd. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Trading Up 0.7 %

Shares of NASDAQ CLBT opened at $19.78 on Tuesday. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of -14.23, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The firm has a 50 day moving average of $18.73 and a 200 day moving average of $20.15.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.